SONNClinical Trials•globenewswire•
Sonnet Releases Virtual Investor "What This Means" Segment
Sentiment:Negative (30)
Summary
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire